Recovery Peptide

TB-500

Thymosin Beta-4 • Systemic Recovery Peptide

TB-500 is commonly used as a synthetic thymosin beta-4 analogue for systemic tendon, ligament, muscle, and soft-tissue recovery. Its reputation is driven by broad tissue-repair biology and extensive community use, while most musculoskeletal evidence remains preclinical.

Tendon & Ligament Muscle Recovery Systemic Use

Protocol Snapshot

TB-500 Quick Reference

Verified Vendors

TB-500

Compare Verified Vendors

Current price and availability
Price per mg and vial-size comparison
Testing and fulfillment details

Compare

View Price Index

Loading Range

2–2.5mg

Twice weekly in common community protocols.

Daily Range

250–500mcg

Often paired with BPC-157 for 4–8 weeks.

Primary Use

Tissue Repair

Tendon, ligament, muscle, and soft-tissue recovery.

Distribution

Systemic

Injection near the injury is not commonly considered necessary.

Peptide Grade

GradeB

Strong tissue-repair biology and widespread recovery reports make TB-500 one of the most compelling community healing peptides, while limited human musculoskeletal research and unresolved angiogenesis-related safety questions keep it at a B.

Research Community Safety

Foundation

Research context, mechanisms, and practical use cases

What Is TB-500?

TB-500 is commonly marketed as a synthetic analogue of thymosin beta-4, a naturally occurring 43-amino-acid protein found in nearly every human and animal cell. The native protein is present in platelets, white blood cells, plasma, wound fluid, and many tissue types.

Thymosin beta-4 was first identified during thymus research in the 1960s. It is involved in cell migration, cytoskeletal organization, blood-vessel formation, inflammation control, and tissue repair. The World Health Organization assigned the International Nonproprietary Name timbetasin to thymosin beta-4.

Its primary molecular role is binding G-actin in a 1:1 ratio. By regulating the pool of actin available for cytoskeletal remodeling, thymosin beta-4 supports cell movement toward damaged tissue and helps coordinate repair. This biology is the foundation for TB-500’s use in recovery communities.

Systemic Distribution

TB-500 is discussed as a systemic peptide rather than a strictly local one. Community protocols generally use standard subcutaneous sites and do not require injection near the injured tissue.

Different regions of thymosin beta-4 contribute to different functions. The N-terminal Ac-SDKP region is associated with anti-inflammatory and antifibrotic effects, while its actin-related activity helps support cell migration, angiogenesis, and tissue remodeling.

TB-500 Benefits

Most benefit claims combine preclinical thymosin beta-4 research with extensive community reports about TB-500. Direct human musculoskeletal trials remain limited.

Tendon & Ligament Recovery

Community interest centers on stubborn connective-tissue injuries, while the supporting musculoskeletal research remains predominantly preclinical.

Muscle Recovery

Users often report less post-injury tightness and an easier return to training, though controlled human evidence remains limited.

Soft-Tissue Repair

Thymosin beta-4 biology is associated with cell migration and tissue remodeling, providing the mechanistic basis for wound-healing interest.

Mobility & Range of Motion

Reduced stiffness and improved movement are recurring community outcomes, especially when the peptide is paired with structured rehabilitation.

Systemic Application

TB-500 is commonly used away from the injury site, making it more convenient when several areas are being rehabilitated.

Inflammation & Remodeling

Preclinical thymosin beta-4 work suggests anti-inflammatory and antifibrotic activity, but the extent to which TB-500 reproduces it in humans is uncertain.

Protocol Planning

Community dosing and reconstitution

TB-500 Dosing Protocol

No published human dose-finding study has established these subcutaneous schedules. They summarize recurring community practices rather than a validated treatment protocol.

Traditional Loading Protocol

Dose

2–2.5mg twice weekly

Weekly Total

4–5mg

Duration

4–6 weeks; chronic injuries are sometimes run longer

After Loading

Stop and reassess, or reduce to less frequent community maintenance

Daily Wolverine Protocol

TB-500

250–500mcg once daily

BPC-157

250–500mcg once daily

Timing

Flexible; fasting is not commonly considered necessary

Duration

4–8 weeks alongside rehabilitation and objective progress tracking

By Application

Acute injury: 4–5mg per week during loading
Chronic injury: 4–5mg per week, often for 8–12 weeks
Post-surgical recovery: 4–6mg per week in community protocols
Maintenance: 2–2.5mg every two weeks

TB-500 Reconstitution

The example below uses a 10mg vial with 2mL of bacteriostatic water.

10mg Vial

BAC Water

2mL

Concentration

5mg/mL

500mcg

10 units on a U-100 insulin syringe

2.5mg

50 units on a U-100 insulin syringe

Reconstitution Calculator

Handling Notes

Mixing

Add bacteriostatic water and gently swirl or roll until dissolved

Storage

Refrigerate after reconstitution

Injection Site

Abdomen or thigh; rotate sites

Injury Location

Community protocols generally do not require injection beside the injury

Anecdotal Data Points

Community-reported outcomes and recurring patterns

Self-reported anecdotal experiences aggregated from public & private peptide community discussions and anonymous peptideprotocols.app user reports. This information does not carry the same weight as published research.

Positive Reports

Reduced discomfort and easier movement within the first one to two weeks are common early reports.
Tendon, ligament, shoulder, elbow, knee, and muscle recovery are the most frequently discussed applications.
Users often describe less stiffness and improved range of motion while progressing through rehabilitation.
Some report that several irritated areas improve at once, reinforcing its reputation as a systemic option.
The TB-500 and BPC-157 combination receives stronger community support than TB-500 alone.

Negative Reports

Some users notice little or no meaningful improvement, particularly with advanced degenerative injuries.
Temporary fatigue, lethargy, or a mild flu-like feeling may occur early in a cycle.
Headache, brief lightheadedness, and injection-site irritation are occasionally reported.
Tendon and ligament changes are often slow, making it difficult to separate peptide effects from rest and rehabilitation.

Stacking & Synergy

Potential TB-500 pairings and tracking context

Relevant Combinations

TB-500 + BPC-157

The Wolverine Stack is the dominant community pairing. TB-500 is positioned as systemic support, while BPC-157 is commonly used for focused connective-tissue and gut-related recovery goals.

TB-500 + GHK-Cu

Sometimes combined for collagen remodeling, wound support, and broader tissue-repair goals. Separate vials avoid uncertainty about long-term compatibility in solution.

Free with login

Track in Journal

Track TB-500 with the markers that matter most for this compound.

Pain during daily movement and training.
Swelling, tenderness, and morning stiffness.
Range of motion, load tolerance, and recovery trend.

Start Tracking

Common Questions

Practical TB-500 context

Why is TB-500 commonly paired with BPC-157?

Community protocols position TB-500 as broader systemic recovery support and BPC-157 as a more targeted connective-tissue option. The pairing is popular, but controlled human combination studies are lacking.

Does TB-500 need to be injected near the injury?

Community protocols generally treat it as systemic and use standard subcutaneous sites such as the abdomen or thigh. Injecting directly beside an injury has not been established as necessary.

How quickly do users notice changes?

Early reports often involve reduced discomfort or stiffness within one to two weeks. Tendon and ligament recovery is usually slower and should be judged through function, range of motion, and rehabilitation milestones rather than pain alone.

Safety Notes

Side effects, contraindications, and precautions

TB-500 Side Effects

Human safety information remains limited, and published tolerability research involving thymosin beta-4 does not establish the long-term safety of common community subcutaneous TB-500 protocols.

Long-term immune, reproductive, cardiovascular, cancer, and organ-safety questions remain unresolved for common subcutaneous protocols.

Commonly Reported

Injection-site redness, tenderness, or irritation.
Temporary fatigue or lethargy.
Headache or brief lightheadedness.

Important Limitations

Angiogenesis and cell-migration effects create unresolved concern in people with active or prior malignancy.
Severe allergic symptoms, chest symptoms, neurological changes, or unexpected swelling require medical evaluation.

TB-500 Contraindications and Precautions

Do Not Use If You Have

Active cancer or an unevaluated history of malignancy.
Known hypersensitivity to thymosin beta-4, TB-500, or formulation ingredients.
Pregnancy or breastfeeding because reproductive safety is unknown.
An acute injury requiring surgical evaluation, fracture stabilization, or emergency care.

Use Caution With

A personal history of cancer because TB-500 promotes cell migration and angiogenesis.
Anticoagulant or antiplatelet therapy because injections may increase bruising.
Autoimmune disease or immunosuppressive treatment because immune effects are incompletely characterized.
Recent surgery, cardiovascular disease, or unexplained swelling.

Drug Interactions

No well-established human drug interactions have been defined. Use caution with anticoagulants, antiplatelet drugs, immunosuppressants, and medications affecting wound healing. Formal interaction studies are lacking.

Monitoring

Track pain, swelling, range of motion, function, injection-site reactions, and objective rehabilitation milestones. Persistent pain, weakness, instability, or loss of function should be medically evaluated rather than masked by peptide use.

Regulatory Status

TB-500 is not FDA approved for human use. The FDA placed thymosin beta-4 on the Category 2 bulk drug substances list, and it is prohibited by the World Anti-Doping Agency under the S0 Unapproved Substances category.

FINAL VERDICT

Peptide Protocol's Opinionated Opinion

This is not medical advice. This editorial is our own opinion piece based off the experience of our own lab rats.

TB-500 has earned its spot in our recovery stacks because it's practical, works systemically, and gets paired with BPC-157 all the time for those stubborn tendon, ligament, and muscle issues that just won't quit.

The best reports we see (and what lines up with our own n=1 runs) are things like less stiffness, better range of motion, and getting back into proper rehab without it feeling like such a grind. It's not some overnight miracle that magically rebuilds everything, but it does help move the needle on recovery.

Biggest knock on it is still the evidence gap. The community stories run way ahead of solid human musculoskeletal data, and long-term safety questions haven't been fully put to bed even though the rep among users is generally solid.

That balance is exactly why we give it a B grade: strong practical tool with real community momentum behind it, but still held back by limited direct human research and those open-ended safety questions.

Bottom line — we use it as a solid adjunct alongside proper diagnosis and rehab, not as a replacement for either.